 Gina Kruse
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 18 | 2025 | 440 | 6.830 |
Why?
| | Early Detection of Cancer | 9 | 2026 | 444 | 2.870 |
Why?
| | Text Messaging | 5 | 2023 | 179 | 2.310 |
Why?
| | Tobacco Use Cessation | 3 | 2025 | 29 | 1.840 |
Why?
| | Smoking | 9 | 2026 | 1603 | 1.780 |
Why?
| | Primary Health Care | 7 | 2023 | 1809 | 1.260 |
Why?
| | Massachusetts | 9 | 2026 | 174 | 1.220 |
Why?
| | Tobacco Use | 3 | 2022 | 65 | 1.070 |
Why?
| | Smokers | 4 | 2020 | 144 | 1.030 |
Why?
| | Varenicline | 2 | 2025 | 29 | 0.990 |
Why?
| | Tobacco Products | 3 | 2025 | 98 | 0.970 |
Why?
| | Colorectal Neoplasms | 4 | 2025 | 805 | 0.970 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2025 | 288 | 0.960 |
Why?
| | Behavior Therapy | 3 | 2025 | 282 | 0.950 |
Why?
| | Tobacco Use Disorder | 3 | 2022 | 245 | 0.920 |
Why?
| | Electronic Nicotine Delivery Systems | 5 | 2025 | 105 | 0.900 |
Why?
| | Intention | 1 | 2026 | 179 | 0.840 |
Why?
| | Postal Service | 2 | 2020 | 31 | 0.820 |
Why?
| | Buprenorphine | 2 | 2025 | 179 | 0.810 |
Why?
| | HIV Infections | 8 | 2025 | 3022 | 0.770 |
Why?
| | Lung Neoplasms | 2 | 2026 | 2567 | 0.740 |
Why?
| | Laboratories | 1 | 2023 | 110 | 0.740 |
Why?
| | Community Health Services | 2 | 2015 | 233 | 0.730 |
Why?
| | United States Indian Health Service | 2 | 2022 | 46 | 0.680 |
Why?
| | Patient Discharge | 3 | 2024 | 933 | 0.660 |
Why?
| | Mentoring | 1 | 2023 | 154 | 0.630 |
Why?
| | Electronic Health Records | 4 | 2016 | 1132 | 0.610 |
Why?
| | Alaska Natives | 1 | 2022 | 154 | 0.610 |
Why?
| | Humans | 59 | 2026 | 141754 | 0.590 |
Why?
| | Health Behavior | 3 | 2022 | 792 | 0.560 |
Why?
| | Papillomavirus Infections | 1 | 2023 | 382 | 0.550 |
Why?
| | Community Health Centers | 5 | 2025 | 63 | 0.550 |
Why?
| | Delivery of Health Care | 4 | 2023 | 962 | 0.540 |
Why?
| | Telemedicine | 3 | 2025 | 894 | 0.540 |
Why?
| | Pilot Projects | 6 | 2025 | 1826 | 0.530 |
Why?
| | Middle Aged | 24 | 2026 | 34647 | 0.530 |
Why?
| | Adult | 29 | 2026 | 39391 | 0.510 |
Why?
| | Female | 37 | 2026 | 75943 | 0.500 |
Why?
| | Rural Population | 3 | 2024 | 606 | 0.500 |
Why?
| | Meaningful Use | 1 | 2016 | 13 | 0.500 |
Why?
| | Male | 32 | 2026 | 70179 | 0.480 |
Why?
| | Indians, North American | 1 | 2022 | 655 | 0.480 |
Why?
| | Comorbidity | 2 | 2017 | 1664 | 0.450 |
Why?
| | Motivation | 2 | 2019 | 603 | 0.450 |
Why?
| | Smoke-Free Policy | 1 | 2014 | 13 | 0.440 |
Why?
| | India | 3 | 2025 | 208 | 0.440 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 53 | 0.430 |
Why?
| | Smoking Prevention | 1 | 2015 | 184 | 0.420 |
Why?
| | Cross-Sectional Studies | 10 | 2026 | 5697 | 0.420 |
Why?
| | Opiate Substitution Treatment | 3 | 2025 | 168 | 0.410 |
Why?
| | Tobacco Smoking | 2 | 2024 | 25 | 0.400 |
Why?
| | Reimbursement, Incentive | 1 | 2013 | 42 | 0.400 |
Why?
| | Program Development | 1 | 2015 | 368 | 0.390 |
Why?
| | Counseling | 4 | 2024 | 398 | 0.390 |
Why?
| | Vaping | 2 | 2025 | 63 | 0.390 |
Why?
| | Colonoscopy | 1 | 2014 | 251 | 0.370 |
Why?
| | Tobacco Smoke Pollution | 1 | 2014 | 256 | 0.360 |
Why?
| | Health Equity | 3 | 2024 | 103 | 0.360 |
Why?
| | Documentation | 1 | 2013 | 199 | 0.350 |
Why?
| | Telephone | 2 | 2023 | 182 | 0.340 |
Why?
| | Population Surveillance | 1 | 2014 | 482 | 0.340 |
Why?
| | Neoplasms | 2 | 2023 | 2747 | 0.330 |
Why?
| | Aged | 13 | 2026 | 24746 | 0.310 |
Why?
| | Hospitalization | 2 | 2021 | 2264 | 0.300 |
Why?
| | Anti-HIV Agents | 2 | 2014 | 860 | 0.300 |
Why?
| | Referral and Consultation | 2 | 2012 | 799 | 0.280 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1634 | 0.280 |
Why?
| | United States | 9 | 2025 | 15310 | 0.260 |
Why?
| | Students | 2 | 2022 | 648 | 0.250 |
Why?
| | Opioid-Related Disorders | 2 | 2025 | 564 | 0.250 |
Why?
| | Oklahoma | 1 | 2026 | 15 | 0.240 |
Why?
| | Boston | 3 | 2024 | 91 | 0.240 |
Why?
| | Flavoring Agents | 1 | 2025 | 13 | 0.230 |
Why?
| | South Africa | 2 | 2024 | 240 | 0.230 |
Why?
| | Feasibility Studies | 2 | 2022 | 1027 | 0.220 |
Why?
| | Appointments and Schedules | 2 | 2002 | 97 | 0.220 |
Why?
| | Occult Blood | 1 | 2024 | 37 | 0.210 |
Why?
| | Pandemics | 3 | 2021 | 1656 | 0.210 |
Why?
| | Faculty | 2 | 2022 | 154 | 0.210 |
Why?
| | Outpatients | 2 | 2024 | 421 | 0.200 |
Why?
| | Patient Compliance | 2 | 2012 | 611 | 0.200 |
Why?
| | Mental Disorders | 2 | 2002 | 1130 | 0.200 |
Why?
| | Social Determinants of Health | 2 | 2024 | 274 | 0.200 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 192 | 0.190 |
Why?
| | Cost-Benefit Analysis | 1 | 2025 | 619 | 0.190 |
Why?
| | Vaginal Smears | 1 | 2023 | 61 | 0.190 |
Why?
| | Safety-net Providers | 1 | 2024 | 124 | 0.190 |
Why?
| | Cooperative Behavior | 1 | 2025 | 463 | 0.190 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2002 | 82 | 0.180 |
Why?
| | Papillomaviridae | 1 | 2023 | 133 | 0.180 |
Why?
| | Interrupted Time Series Analysis | 1 | 2022 | 80 | 0.180 |
Why?
| | Medically Underserved Area | 1 | 2022 | 100 | 0.180 |
Why?
| | Treatment Refusal | 1 | 2002 | 96 | 0.180 |
Why?
| | Student Run Clinic | 1 | 2021 | 2 | 0.180 |
Why?
| | Mass Screening | 3 | 2025 | 1313 | 0.180 |
Why?
| | Tuberculosis | 1 | 2024 | 286 | 0.180 |
Why?
| | Patient Participation | 1 | 2005 | 432 | 0.170 |
Why?
| | Pain Management | 1 | 2005 | 396 | 0.170 |
Why?
| | Medication Adherence | 1 | 2025 | 513 | 0.170 |
Why?
| | Education, Medical, Undergraduate | 1 | 2023 | 196 | 0.160 |
Why?
| | Developing Countries | 2 | 2015 | 318 | 0.160 |
Why?
| | Physician-Patient Relations | 1 | 2005 | 585 | 0.160 |
Why?
| | Prevalence | 4 | 2025 | 2799 | 0.160 |
Why?
| | Community Networks | 1 | 2020 | 58 | 0.160 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2938 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2024 | 587 | 0.150 |
Why?
| | Education, Medical | 1 | 2023 | 271 | 0.150 |
Why?
| | Interviews as Topic | 3 | 2019 | 854 | 0.150 |
Why?
| | Crisis Intervention | 1 | 2019 | 33 | 0.150 |
Why?
| | Pain | 1 | 2005 | 781 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 1123 | 0.140 |
Why?
| | Preventive Health Services | 1 | 2020 | 154 | 0.140 |
Why?
| | Nevirapine | 2 | 2008 | 18 | 0.140 |
Why?
| | Cohort Studies | 5 | 2025 | 5815 | 0.140 |
Why?
| | Students, Medical | 1 | 2023 | 369 | 0.140 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2026 | 1406 | 0.140 |
Why?
| | Young Adult | 6 | 2025 | 13749 | 0.130 |
Why?
| | Organophosphonates | 2 | 2008 | 99 | 0.130 |
Why?
| | Decision Making | 1 | 2005 | 961 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2019 | 5974 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2024 | 768 | 0.130 |
Why?
| | Deoxycytidine | 2 | 2008 | 200 | 0.130 |
Why?
| | Adolescent | 8 | 2025 | 22130 | 0.130 |
Why?
| | Communication | 1 | 2023 | 951 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 374 | 0.120 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2008 | 186 | 0.120 |
Why?
| | Texas | 4 | 2005 | 262 | 0.120 |
Why?
| | Hypertension | 1 | 2024 | 1254 | 0.120 |
Why?
| | Diabetes Mellitus | 1 | 2024 | 1077 | 0.120 |
Why?
| | Diffusion of Innovation | 1 | 2016 | 97 | 0.120 |
Why?
| | Caregivers | 1 | 2024 | 943 | 0.120 |
Why?
| | Adenine | 2 | 2008 | 331 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 1 | 2026 | 2765 | 0.110 |
Why?
| | Focus Groups | 2 | 2022 | 572 | 0.110 |
Why?
| | Allied Health Personnel | 1 | 2015 | 53 | 0.110 |
Why?
| | Automobiles | 1 | 2014 | 18 | 0.110 |
Why?
| | Health Surveys | 1 | 2017 | 513 | 0.110 |
Why?
| | Qualitative Research | 2 | 2019 | 1547 | 0.110 |
Why?
| | Community Health Workers | 1 | 2015 | 76 | 0.110 |
Why?
| | Logistic Models | 3 | 2017 | 2092 | 0.110 |
Why?
| | Uganda | 1 | 2014 | 87 | 0.110 |
Why?
| | Colonic Polyps | 1 | 2014 | 83 | 0.100 |
Why?
| | Odds Ratio | 3 | 2008 | 1057 | 0.100 |
Why?
| | Program Evaluation | 2 | 2020 | 930 | 0.100 |
Why?
| | Residence Characteristics | 2 | 2014 | 368 | 0.100 |
Why?
| | Patient Admission | 1 | 2014 | 203 | 0.100 |
Why?
| | Managed Care Programs | 1 | 2013 | 140 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1146 | 0.090 |
Why?
| | Hospitals, Psychiatric | 2 | 2002 | 27 | 0.090 |
Why?
| | Social Class | 1 | 2014 | 268 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2021 | 1133 | 0.090 |
Why?
| | Health Services Accessibility | 4 | 2024 | 1027 | 0.090 |
Why?
| | Prospective Studies | 3 | 2025 | 7777 | 0.090 |
Why?
| | HIV-1 | 2 | 2008 | 895 | 0.090 |
Why?
| | Nurses | 1 | 2014 | 184 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 881 | 0.090 |
Why?
| | Feedback | 1 | 2012 | 179 | 0.090 |
Why?
| | Health Plan Implementation | 1 | 2012 | 145 | 0.090 |
Why?
| | Quality Assurance, Health Care | 1 | 2013 | 333 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2024 | 5212 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2193 | 0.080 |
Why?
| | Hospitals | 1 | 2014 | 696 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2537 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2022 | 16374 | 0.070 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2007 | 87 | 0.070 |
Why?
| | Chronic Disease | 1 | 2013 | 1820 | 0.060 |
Why?
| | Patient Care Team | 1 | 2012 | 673 | 0.060 |
Why?
| | Drug Resistance, Viral | 1 | 2007 | 120 | 0.060 |
Why?
| | Anti-Retroviral Agents | 1 | 2008 | 245 | 0.060 |
Why?
| | Renal Insufficiency | 1 | 2008 | 169 | 0.060 |
Why?
| | Behavioral Risk Factor Surveillance System | 1 | 2025 | 54 | 0.060 |
Why?
| | Risk Factors | 2 | 2014 | 10482 | 0.060 |
Why?
| | Insurance, Health | 2 | 2005 | 299 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2024 | 7923 | 0.060 |
Why?
| | Regression Analysis | 2 | 2005 | 1023 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2022 | 239 | 0.050 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2008 | 408 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2022 | 1041 | 0.050 |
Why?
| | Quality Improvement | 1 | 2012 | 1254 | 0.050 |
Why?
| | Vaccination | 2 | 2022 | 1472 | 0.050 |
Why?
| | Housing | 1 | 2024 | 146 | 0.050 |
Why?
| | Social Networking | 1 | 2023 | 35 | 0.050 |
Why?
| | Mobile Health Units | 1 | 2022 | 21 | 0.050 |
Why?
| | Rural Health Services | 1 | 2004 | 141 | 0.050 |
Why?
| | Midwestern United States | 1 | 2002 | 44 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2003 | 73 | 0.050 |
Why?
| | Health Status | 2 | 2005 | 824 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2022 | 127 | 0.050 |
Why?
| | Hospitals, University | 1 | 2002 | 175 | 0.050 |
Why?
| | Bupropion | 1 | 2022 | 46 | 0.050 |
Why?
| | Stakeholder Participation | 1 | 2022 | 83 | 0.040 |
Why?
| | Schools, Medical | 1 | 2023 | 152 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2007 | 747 | 0.040 |
Why?
| | Quality of Life | 2 | 2022 | 3014 | 0.040 |
Why?
| | Continuity of Patient Care | 1 | 2004 | 287 | 0.040 |
Why?
| | England | 1 | 2021 | 108 | 0.040 |
Why?
| | Meals | 1 | 2022 | 132 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2022 | 170 | 0.040 |
Why?
| | HIV | 1 | 2022 | 250 | 0.040 |
Why?
| | Data Collection | 1 | 2024 | 662 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 278 | 0.040 |
Why?
| | Poverty | 1 | 2024 | 530 | 0.040 |
Why?
| | Urban Population | 1 | 2003 | 485 | 0.040 |
Why?
| | Triage | 1 | 2021 | 246 | 0.040 |
Why?
| | Medicaid | 1 | 2003 | 451 | 0.040 |
Why?
| | Learning | 1 | 2023 | 439 | 0.040 |
Why?
| | Zambia | 2 | 2008 | 57 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2012 | 11181 | 0.030 |
Why?
| | Medicare | 1 | 2003 | 808 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1570 | 0.030 |
Why?
| | Emtricitabine | 2 | 2008 | 205 | 0.030 |
Why?
| | Tenofovir | 2 | 2008 | 285 | 0.030 |
Why?
| | Curriculum | 1 | 2023 | 1039 | 0.030 |
Why?
| | Child | 2 | 2024 | 22414 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3597 | 0.020 |
Why?
| | Socioeconomic Factors | 2 | 2004 | 1317 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 521 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2008 | 285 | 0.020 |
Why?
| | Creatinine | 1 | 2008 | 490 | 0.020 |
Why?
| | Risk | 1 | 2008 | 907 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1268 | 0.010 |
Why?
| | Pregnancy | 2 | 2008 | 7092 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2008 | 752 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2004 | 163 | 0.010 |
Why?
| | Office Visits | 1 | 2003 | 95 | 0.010 |
Why?
| | Health Care Surveys | 1 | 2003 | 566 | 0.010 |
Why?
| | Disease Progression | 1 | 2008 | 2800 | 0.010 |
Why?
| | Biomarkers | 1 | 2008 | 4190 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2007 | 6289 | 0.010 |
Why?
|
|
Kruse's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|